Study Title
A Phase 3 Trial of Brentuximab Vedotin (SGN-35) Versus Physician’s Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma (NCT01578499)
Trial Description
This is a Randomized, Open-Label, Phase III trial of brentuximab vedotin (also known as SGN-35) versus Physician’s choice (Methotrexate or Bexarotene) in Patients with CD30-Positive Cutaneous T-Cell Lymphoma.
This trial is sponsored by Millennium Pharmaceuticals/ Seattle Genetics. [1]
Study Data
- Condition: Lymphoma
- Interventions:
- Drugs used in this trial
- Brentuximab vedotin (Adcetris®; Seattle Genetics, Inc.)
- Methotrexate (Trexall®; Teva Pharmaceuticals) or
- Bexarotene (Targretin®; Valeant Pharmaceuticals Inc.)
- Drugs used in this trial
- Phase: III
- Estimated Enrollment: 132
- Start: August 2012
- Estimated Completion: July 2018
- Last verified: January 2016
Study Schematic
Last Editorial review: July 17, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.
